Photo from wikipedia
Although FDA recommended pharmacogenetic testing and alternative antiplatelet agents in CYP2C19 loss-of-function(LoF) allele carriers in patients treated with clopidogrel, implementation in practice has been minimal. Appropriate P2Y12 receptor antagonist therapy… Click to show full abstract
Although FDA recommended pharmacogenetic testing and alternative antiplatelet agents in CYP2C19 loss-of-function(LoF) allele carriers in patients treated with clopidogrel, implementation in practice has been minimal. Appropriate P2Y12 receptor antagonist therapy following PCI based on bedside
Keywords:
cyp2c19 genotype;
implementation;
antiplatelet;
bedside testing;
therapy;
testing cyp2c19
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!